Sofwave Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Achieves Full-Year Profitability

Core Insights - Sofwave Medical Ltd reported record fourth quarter revenue of $28.9 million, a 58% year-over-year increase, and achieved full-year IFRS profitability in 2025, marking a significant milestone in the company's growth [1][3]. Financial Highlights - Fourth quarter revenue reached approximately $28.9 million, reflecting a 58% increase compared to the same quarter in 2024 [3][6]. - Full fiscal year 2025 revenue totaled approximately $87.6 million, representing a 47% growth over 2024 [3][6]. - The company achieved net profitability for the full fiscal year 2025, with IFRS net income of $5.5 million compared to a net loss of $4.5 million in the previous year [5][6]. - Gross margin for the fourth quarter was 75.6%, while the full fiscal year gross margin was 75.3% [6][8]. - Recurring revenue for the fourth quarter was $13.2 million, an 83% year-over-year increase, and accounted for 46% of total revenue [6][8]. Business Strategy and Market Position - Sofwave is well-positioned to capitalize on the growing demand for regenerative and non-invasive aesthetic treatments, particularly in response to emerging needs related to GLP-1 and skin laxity [4][5]. - The company has a strategic growth plan focused on sustainable, innovative, non-invasive solutions, including the upcoming Pure Impact VIP™ technology for muscle strengthening and toning [5][10]. - Sofwave's brand recognition is increasing, with over 2,700 systems sold and more than 770,000 treatments administered since commercialization [8][10]. Operational Highlights - The installed base of Sofwave systems continues to expand globally, with systems placed in over 50 countries [5][8]. - Cash from operating activities for the fourth quarter was $8.5 million, a significant increase from $0.4 million in the same period last year [6][8].